
Opinion|Videos|October 14, 2024
Exploring the Kidney-CHAMP Study
Key Takeaways
- The trial focused on improving cardiovascular risk management in type 2 diabetes through a coordinated care model involving healthcare systems.
- Interventions included educational sessions, feedback, and support for healthcare providers to enhance adherence to guideline-directed medical therapy.
A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Tell us about Kidney-CHAMP study.
- What were the objectives of Kidney-CHAMP and how was the study designed?
- What interventions were provided?
- What were the results of the study?
- What are future opportunities to improve CRM care based on this study?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.

Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.

Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.

The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
4
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
5

